Other News To Note
Monday, March 19, 2012
Anthera Pharmaceuticals Inc., of Hayward, Calif., said it cut its headcount by about 45 percent and will reduce or eliminate vendor activities in the wake of the recent termination of the VISTA-16 Phase III trial for futility. The company reported last week that it would cease patient enrollment and dosing in VISTA-16, which was testing sPLA2 inhibitor varespladib in acute coronary syndrome.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.